Last reviewed · How we verify
Traditional Cryoprecipitate
Cryoprecipitate is a blood product concentrate that replaces deficient clotting factors and fibrinogen to restore hemostatic function in patients with bleeding disorders.
Cryoprecipitate is a blood product concentrate that replaces deficient clotting factors and fibrinogen to restore hemostatic function in patients with bleeding disorders. Used for Fibrinogen deficiency or dysfibrinogenemia with active bleeding, Factor VIII deficiency (hemophilia A) when specific factor concentrates unavailable, von Willebrand disease with severe bleeding.
At a glance
| Generic name | Traditional Cryoprecipitate |
|---|---|
| Sponsor | Weill Medical College of Cornell University |
| Drug class | Blood product; clotting factor concentrate |
| Target | Fibrinogen, Factor VIII, von Willebrand factor, Fibronectin, Factor XIII |
| Modality | Biologic |
| Therapeutic area | Hematology; Hemostasis and Thrombosis |
| Phase | FDA-approved |
Mechanism of action
Cryoprecipitate is prepared by thawing fresh frozen plasma at cold temperatures, causing fibrinogen, fibronectin, von Willebrand factor, factor VIII, and factor XIII to precipitate out. When transfused, these concentrated clotting factors restore the patient's ability to form stable blood clots and control bleeding. It is used primarily in acute bleeding situations where rapid fibrinogen replacement is needed.
Approved indications
- Fibrinogen deficiency or dysfibrinogenemia with active bleeding
- Factor VIII deficiency (hemophilia A) when specific factor concentrates unavailable
- von Willebrand disease with severe bleeding
- Disseminated intravascular coagulation (DIC) with fibrinogen depletion
- Massive transfusion protocols for acute hemorrhage
Common side effects
- Allergic reaction
- Transfusion-related acute lung injury (TRALI)
- Thromboembolic events
- Fever
- Chills
Key clinical trials
- Ablation Compare With Surgery for Early Breast Cancer (NA)
- Utility of Intermittent Cryo-Compression Versus Traditional Icing Following Arthroscopic Rotator Cuff Repair (NA)
- Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding (PHASE4)
- Safety of Lung Cryobiopsy in People With Cancer (PHASE2)
- EFFECT OF CRYOTHERAPY ON KINEMATIC GAIT PARAMETERS IN PATIENTS WITH CHRONIC PATELLOFEMORAL PAIN SYNDROME (NA)
- Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer (NA)
- Atrial Fibrillation Ablation The Hybrid Approach Versus Traditional Management (EARLY_PHASE1)
- Oocyte Cryopreservation by Slow Freezing and Vitrification (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Traditional Cryoprecipitate CI brief — competitive landscape report
- Traditional Cryoprecipitate updates RSS · CI watch RSS
- Weill Medical College of Cornell University portfolio CI